9.09
+8.73%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Harvard Bioscience
From its filings with the US Securities and Exchange Commission
Harvard Bioscience is based in Holliston, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker HBIO. The SEC classifies its business as laboratory analytical instruments. In the fiscal year to 31 December 2025, it reported revenue of $86.5m and a net loss of $56.7m. At that date it held total assets of $80.1m and shareholders' equity of $13.7m. By business, Instruments, Equipment, Software, and Accessories [Member] brought in 90.4% of revenue, followed by Service, Maintenance, and Warranty Contracts [Member] at 9.6%. By region, UNITED STATES accounted for 45.0%, followed by EMEA [Member] at 30.9% and CHINA at 12.7%.
Harvard Bioscience, Inc., a Delaware corporation, is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Our products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations (“CROs”). With operations in the United States, Europe and China, we sell through a combination of direct and distribution channels to customers around the world.
Our business began in 1901, under the name Harvard Apparatus. It was founded by Dr. William T. Porter, a Professor of Physiology at Harvard Medical School and a pioneer of physiology education. We have grown over the years with the development and evolution of modern life science research and education. Our early inventions included ventilators based on Dr. Porter’s design, the mechanical syringe pump for drug infusion in the 1950s, and the microprocessor-controlled syringe pump in the 1980s. In 1996, a group of investors acquired a majority of the then existing business of our predecessor, Harvard Apparatus, Inc. Harvard Bioscience, Inc. was incorporated in the State of Delaware in September 2000 and became the successor entity to Harvard Apparatus, Inc. by merger in November 2000. In 2018, we acquired Data Sciences International, Inc.
Quoted from its 10-K, filed 13 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 21 Oct 2013
- Employees
- 316
- Website
- harvardbioscience.com ↗
- Head office
- 84 OCTOBER HILL RD, HOLLISTON, MA, 01746
- Incorporated in
- DE
- Classification
- Laboratory Analytical Instruments
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. John DukePresident, Chief Executive Officer, Director, since 2025
- Mr. Mark FrostInterim Chief Financial Officer, Treasurer
- Ms. Katherine EadeLead Independent Director$223,000
- Mr. Stephen DeNelskyDirector
- Mr. Robert BensonIndependent Director
- Mr. Robert GagnonIndependent Director, since 2013$598,505
- Mr. Sandy MartinInvestor Relations, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 12
- Environment
- 12
- Social
- 17
- Governance
- 6
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Harvard Bioscience Inc has established itself as a leading player in the bioscience industry, with a wealth of knowledge and experience in developing and manufacturing innovative scientific instruments and tools. This expertise gives the company a competitive advantage in understanding the needs of its target market and providing tailored solutions.
- The company offers a wide range of high-quality products, including laboratory equipment, consumables, and specialized research tools. Harvard Bioscience’s diverse product portfolio enables it to serve various segments within the bioscience industry, catering to different customer requirements and maximizing revenue potential.
- Harvard Bioscience Inc invests significantly in research and development activities to drive product innovation and stay ahead of the market. Its strong R&D capabilities enable the company to introduce cutting-edge technologies and solutions that meet emerging customer demands, enhancing its competitive position.
Weaknesses
- A significant portion of Harvard Bioscience's revenue comes from a few key customers. This dependency poses a risk to the company as any loss of these customers or decline in their orders could have a substantial impact on its financial performance. Diversifying the customer base would help mitigate this vulnerability.
- While Harvard Bioscience has a global customer base, its geographic presence remains relatively limited. This concentration exposes the company to regional economic factors and regulatory changes in specific markets. Expanding into new geographies would reduce the company's dependence on any single market and create additional growth opportunities.
Opportunities
- The global bioscience industry is experiencing a rapid expansion, driven by increased investments in research and development activities in various sectors, including pharmaceuticals, biotechnology, and academia. This growth presents Harvard Bioscience with opportunities to capitalize on rising demand for its research tools and equipment.
- The continuous advancements in fields such as genomics, proteomics, and molecular biology provide Harvard Bioscience with an opportunity to develop and introduce innovative products that cater to these evolving research needs. By staying at the forefront of technological breakthroughs, the company can gain a competitive edge.
Threats
- The bioscience industry is intensely competitive, with numerous companies vying for market share. Harvard Bioscience faces competition from both established players and emerging startups. This competitive landscape puts pressure on pricing, requires continuous innovation, and increases the challenges of maintaining market leadership.
- The bioscience industry is subject to strict regulations and compliance requirements, which can create barriers to entry and affect product development timelines. Harvard Bioscience must remain compliant with these regulations to ensure the quality and safety of its products while also navigating the associated costs and complexities.
- The global economic uncertainty and market volatility can impact Harvard Bioscience's business, as spending on research and development activities may fluctuate during economic downturns. The company must be prepared to adapt its strategies and manage its resources effectively in response to changing market conditions.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.